Thomas Ryan Net Worth

The estimated Net Worth of Thomas F Jr Ryan is at least $5.59 Million dollars as of 1 March 2022. Mr. Ryan owns over 2,000 units of Repligen stock worth over $208,934 and over the last 21 years he sold RGEN stock worth over $5,195,696. In addition, he makes $190,204 as Independent Director at Repligen.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Ryan RGEN stock SEC Form 4 insiders trading

Thomas has made over 29 trades of the Repligen stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of RGEN stock worth $396,060 on 1 March 2022.

The largest trade he's ever made was selling 86,039 units of Repligen stock on 13 May 2013 worth over $775,211. On average, Thomas trades about 6,111 units every 134 days since 2003. As of 1 March 2022 he still owns at least 1,457 units of Repligen stock.

You can see the complete history of Mr. Ryan stock trades at the bottom of the page.

Thomas Ryan biography

Thomas F. Ryan Jr. serves as Independent Director of the Company. Mr. Ryan is currently an investor in various private companies. Mr. Ryan served as the President and Chief Operating Officer of the American Stock Exchange from October 1995 to April 1999. Prior to 1995, he held a variety of positions at the investment banking firm of Kidder, Peabody & Co., Inc., serving as the firm’s Chairman in 1995. He holds a B.A. from Boston College and is a graduate of the Boston Latin School. Mr. Ryan is a director for the New York State Independent System Operator and a director for BNY Mellon Asset Management Mutual Funds Board. Mr. Ryan’s qualifications to sit on the Company’s Board of Directors include his years of experience in the areas of securities trading and investment banking.

What is the salary of Thomas Ryan?

As the Independent Director of Repligen, the total compensation of Thomas Ryan at Repligen is $190,204. There are 8 executives at Repligen getting paid more, with Anthony Hunt having the highest compensation of $4,424,560.

How old is Thomas Ryan?

Thomas Ryan is 78, he's been the Independent Director of Repligen since 2003. There are no older and 11 younger executives at Repligen.

What's Thomas Ryan's mailing address?

Thomas's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM, MA, 02453.

Insiders trading at Repligen

Over the last 21 years, insiders at Repligen have traded over $118,224,292 worth of Repligen stock and bought 160,440 units worth $1,459,521 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Glenn P Muir, and Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of $3,015,702. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth $1,139,034.

What does Repligen do?

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

Complete history of Mr. Ryan stock trades at Repligen

Repligen executives and stock owners

Repligen executives and other stock owners filed with the SEC include:

• Anthony Hunt,
  President, Chief Executive Officer, Director
• Jon Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Senior Vice President - Research and Development
• Anthony J. Hunt,
  CEO, Pres & Director
• Jon K. Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Sr. VP of R&D
• Karen Dawes,
  Independent Chairperson of the Board
• Glenn Muir,
  Independent Director
• Thomas Ryan,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• Rohin Mhatre,
  Independent Director
• Carrie Eglinton,
  Director
• James Slaughter,
  Chief HR Officer
• James R. Bylund,
  Chief Operating Officer
• Christine Gebski,
  Sr. VP of Filtration & Chromatography
• Ken Elmer,
  Global Head of HR
• Rachel Goodrich,
  VP of Marketing
• Stephen Tingley,
  VP of Global Sales
• Squire Servance,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Sondra S. Newman,
  Global Head of Investor Relations
• Jim Bylund,
  Sr. VP of Operations & Information Technology
• Jason K Garland,
  CFO
• Glenn L Md Cooper,
  Director
• James R Rusche,
  Senior Vice President
• John Cox,
  Director
• Howard Benjamin,
  
• Roy T Eddleman,
  10% owner
• Christine Gebski,
  See Remarks
• G William Miller,
  Director
• Timothy Scott Harris,
  
• Barbara Burnim Day,
  Vice President
• Daniel W Muehl,
  CFO
• Partners L P/Ilbiotechnolog...,
  
• Alfred Lewis Goldberg,
  Director
• Walter C Herlihy,
  PRESIDENT, CEO
• Michael A Griffith,
  Director
• Daniel P Witt,
  Vice President
• Jonathan I Lieber,
  CFO
• Earl Webb Henry,
  Director
• William J Kelly,
  Vice President
• Alexander Rich,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Hal Landy,
  Vice President
• Paul Schimmel,
  Director
• Laura Whitehouse,
  Vice President
• Robert J Hennessey,
  Director
• Margaret Pax,
  
• Konstantin Konstantinov,
  
• Martin D Madaus,
  
• James Bylund,
  Chief Operating Officer
• Olivier Loeillot,
  Chief Executive Officer